MRI to quantify renal tumour motion: an observational study in order to develop a radiation treatment for renal cancer.

Published: 11-04-2011
Last updated: 27-04-2024

To quantify renal tumour motion using MRI.

Ethical review	Approved WMO
Status	Recruitment stopped
Health condition type	Renal and urinary tract neoplasms malignant and unspecified
Study type	Observational invasive

Summary

ID

NL-OMON38074

Source
ToetsingOnline

Brief title
MRI to quantify renal tumour motion.

Condition

- Renal and urinary tract neoplasms malignant and unspecified
- Renal disorders (excl nephropathies)

Synonym
Kidney tumour, Renal lesion

Research involving
Human

Sponsors and support

Primary sponsor: Universitair Medisch Centrum Utrecht
Source(s) of monetary or material Support: Ministerie van OC&W

Intervention

Keyword: MRI, Radiotherapy, Renal tumour

Outcome measures

Primary outcome

Quantify renal tumour movement with MRI.

Secondary outcome

Determine the reproducibility of a renal tumour position during multiple

breath-holds.

Study description

Background summary

Non-metastasised renal tumours are currently treated with a whole or partial nephrectomy. Radiotherapy is a non-invasive alternative treatment for renal tumours. To avoid normal tissue damage during radiotherapy image-guidance with good soft tissue contrast, only available in MRI, should be present. An MRI accelerator, which is a combination of a radiotherapy treatment machine and an MRI scanner, will be clinically available in about two years. An MRI accelerator will enable to detect the tumour position real-time during the radiotherapy treatment and will, non-invasively, be able to spare much healthy kidney tissue. To design a treatment on the MRI-accelerator the tumour motion should be known.

Study objective

To quantify renal tumour motion using MRI.

Study design

Observational study to investigate kidney and renal tumour motion.

Study burden and risks

Patients will undergo one MRI scan of approximately 30 minutes. No contrast will be administered. The use of MRI is after proper screening free of any

risks. For the patients included in the study there is no individual benefit.

Contacts

Public
Universitair Medisch Centrum Utrecht

Heidelberglaan 100
3584CX Utrecht
NL
Scientific
Universitair Medisch Centrum Utrecht

Heidelberglaan 100
3584CX Utrecht
NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age
Adults (18-64 years)
Elderly (65 years and older)

Inclusion criteria

- Renal leasion
- Written informed consent

Exclusion criteria

- Patients who meet exclusion criteria for MRI following the protocol of the department of radiology UMCU.

Study design

Design

Study type: Observational invasive

Masking:	Open (masking not used)
Control:	Uncontrolled
Primary purpose:	Diagnostic

Recruitment

NL

Recruitment status:	Recruitment stopped
Start date (anticipated):	23-06-2011
Enrollment:	23
Type:	Actual

Ethics review

Approved WMO

Date:	11-04-2011
Application type:	First submission
Review commission:	METC Universitair Medisch Centrum Utrecht (Utrecht)

Approved WMO

Date:	24-04-2012
Application type:	Amendment
Review commission:	METC Universitair Medisch Centrum Utrecht (Utrecht)

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
CCMO	NL35291.041.11